Project Grant R01CA300246
Award Date
4/9/25
Completion Date
3/31/30
Dollars Obligated
$570K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This $582,198 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by Northwestern University to investigate the role of the protein EZH2 in regulating PARP1 and PARP inhibitor resistance in prostate cancer. The research aims to identify how EZH2-mediated methylation of PARP1 affects its function in DNA damage repair and transcription, with the goal of developing new inhibitors targeting EZH2 and PARP1 to overcome PARP...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $663,713.00 to Emory University to develop a series of proteolysis targeting chimeras (PROTACs) that can degrade EZH2 proteins and block their non-enzymatic functions in prostate cancer. The project aims to address limitations of existing EZH2 inhibitors by creating PROTACs that can degrade both PRC2-bound and free/solo EZH2 proteins, ultimately disassociating all EZH2 complexes...
The federal Project Grant award of $371,719 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research at the University of Pennsylvania to investigate the role of the epigenetic modifier NSD2 in prostate cancer progression. The primary aims are to gain deeper mechanistic understanding of how NSD2 influences the chromatin landscape to facilitate the assembly of the androgen receptor (AR) enhanceosome complex, and to evaluate...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Case Western Reserve University aims to advance the understanding of androgen receptor (AR) mechanisms in metastatic castration-resistant prostate cancer (mCRPC). The $606,869 award, effective from July 2024 to June 2029, will utilize sophisticated molecular biology and computational techniques to map the epigenetic mechanisms driving mCRPC tumor growth. The project will explore how small...
The National Cancer Institute (NCI) awarded a $661,072 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Northwestern University to develop a novel therapy with dual immuno-oncology targeting capabilities for the treatment of triple negative breast cancer. The project aims to conduct IND-enabling studies for a first-in-class USP22-specific small molecule inhibitor that can impair cancer cell growth, stemness, and boost anti-tumor immunity. This research aligns with the NCI's goals to...
This federal Project Grant award for $472,458, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at the University of Texas Southwestern Medical Center to investigate the regulation of the PTPN1 gene and its role in the transition of prostate cancer cells to a therapy-resistant neuroendocrine phenotype. The key goals are to: 1) examine how anti-androgen therapy influences PTPN1 expression, 2) uncover the regulatory...
The National Cancer Institute (NCI) awarded a $549,357 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Washington University in St. Louis to conduct research on regulating the androgen receptor (AR) in prostate cancer. The key objectives of the 5-year project are: Determine the mechanism by which the long non-coding RNA NXTAR is suppressed in castration-resistant prostate cancers (CRPCs). Synthesize PSMA-targeted nanoparticles loaded with the NXTAR-N5 oligonucleotide, the ACK1...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $509,246 to the Regents of the University of Michigan to conduct research aimed at understanding the early drivers of prostate cancer lineage plasticity. The research project, titled "Targeting Early Drivers of Prostate Cancer Lineage Plasticity", seeks to identify key transcriptional regulators that initiate the loss of androgen receptor signaling and promote...
This $627,474 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Dana-Farber Cancer Institute, Inc. (DFCI) aims to utilize epigenomic methods and signatures to inform the understanding of lineage plasticity, including treatment-emergent neuroendocrine prostate cancer (NEPC), and to use epigenomic signatures to predict enzalutamide resistance. Specifically, the project will endeavor to identify clinically relevant NEPC...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $653,897 to the University of Virginia to develop novel small molecule inhibitors of the transcription factor ERG as a new approach for the treatment of prostate cancer. The project aims to further optimize these inhibitors for potency and specificity, and then evaluate their preclinical efficacy on prostate cancer cell lines, patient tissue models, and patient-derived xenografts. A...